| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Eren Z et al. | Effects of paricalcitol and aliskiren combination therapy on experimental diabetic nephropathy model in rats. | 2014 | Kidney Blood Press. Res. | pmid:25532067 |
| Duffy MM et al. | Mesenchymal stem cells and a vitamin D receptor agonist additively suppress T helper 17 cells and the related inflammatory response in the kidney. | 2014 | Am. J. Physiol. Renal Physiol. | pmid:25339699 |
| Sahin I et al. | Paricalcitol counteracts the increased contrast induced nephropathy caused by renin-angiotensin-aldosterone system blockade therapy in a rat model. | 2014 | Eur Rev Med Pharmacol Sci | pmid:25339484 |
| Guo C et al. | Synergistic induction of human cathelicidin antimicrobial peptide gene expression by vitamin D and stilbenoids. | 2014 | Mol Nutr Food Res | pmid:24039193 |
| Chen S and Gardner DG | Liganded vitamin D receptor displays anti-hypertrophic activity in the murine heart. | 2013 | J. Steroid Biochem. Mol. Biol. | pmid:22989481 |
| El-Khoury JM et al. | Does Paricalcitol (Zemplar®) interfere with 1,25-dihydroxyvitamin D measurement by liquid chromatography-tandem mass spectrometry assays? | 2013 | Clin. Chim. Acta | pmid:23142648 |
| Pérez V et al. | Magnetic bead-based proteomic technology to study paricalcitol effect in kidney transplant recipients. | 2013 | Eur. J. Pharmacol. | pmid:23567070 |
| Gonzalez E et al. | Effects of oral paricalcitol on secondary hyperparathyroidism and proteinuria of kidney transplant patients. | 2013 | Transplantation | pmid:23545517 |
| Moe SM and Thadhani R | What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials? | 2013 | Curr. Opin. Nephrol. Hypertens. | pmid:24100218 |
| Sharma A et al. | Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients. | 2013 | J Med Econ | pmid:23834479 |
| Havakuk O et al. | Effect of vitamin D analogues on acute cardiorenal syndrome: a laboratory rat model. | 2013 | Isr. Med. Assoc. J. | pmid:24511650 |
| Hojs N et al. | Paricalcitol reduces proteinuria in non-dialysis chronic kidney disease patients. | 2013 | Ther Apher Dial | pmid:23931873 |
| de Boer IH et al. | Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease. | 2013 | Kidney Int. | pmid:22913981 |
| Azak A et al. | Effect of novel vitamin D receptor activator paricalcitol on renal ischaemia/reperfusion injury in rats. | 2013 | Ann R Coll Surg Engl | pmid:24112495 |
| Chen B et al. | Synthesis of VS-105: A novel and potent vitamin D receptor agonist with reduced hypercalcemic effects. | 2013 | Bioorg. Med. Chem. Lett. | pmid:24035340 |
| Larsen T et al. | Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial. | 2013 | BMC Nephrol | pmid:23889806 |
| Nigwekar SU and Thadhani RI | Shining light on vitamin D trials in chronic kidney disease. | 2013 | Kidney Int. | pmid:23364588 |
| Atchison DK et al. | Vitamin D increases plasma renin activity independently of plasma Ca2+ via hypovolemia and β-adrenergic activity. | 2013 | Am. J. Physiol. Renal Physiol. | pmid:23926179 |
| Amer H et al. | Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: results of an open label randomized trial. | 2013 | Am. J. Transplant. | pmid:23601186 |
| Bae S et al. | Vitamin D signaling pathway plays an important role in the development of heart failure after myocardial infarction. | 2013 | J. Appl. Physiol. | pmid:23429874 |
| Duplancic D et al. | The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection. | 2013 | Clin Interv Aging | pmid:23430986 |
| Sánchez-Ãlvarez JE et al. | Paricalcitol reduces proteinuria but does not modify peritoneal protein loss in patients on peritoneal dialysis. | 2013 | Nefrologia | pmid:23364628 |
| Piñera-Haces C et al. | Double treatment with paricalcitol-associated calcifediol and cardiovascular risk biomarkers in haemodialysis. | 2013 | Nefrologia | pmid:23364629 |
| Dyer CA | Safety and tolerability of paricalcitol in patients with chronic kidney disease. | 2013 | Expert Opin Drug Saf | pmid:23621417 |
| Axelsson J et al. | Scavengers of reactive oxygen species, paracalcitol, RhoA, and Rac-1 inhibitors and tacrolimus inhibit angiotensin II-induced actions on glomerular permeability. | 2013 | Am. J. Physiol. Renal Physiol. | pmid:23657856 |
| Verouti SN et al. | Paricalcitol effects on activities and metabolism of platelet activating factor and on inflammatory cytokines in hemodialysis patients. | 2013 | Int J Artif Organs | pmid:23335378 |
| Pérez-Gómez MV et al. | Vitamin D and proteinuria: a critical review of molecular bases and clinical experience. | 2013 | Nefrologia | pmid:24089164 |
| de Lorenzo A et al. | Oral paricalcitol as antiproteinuric agent in chronic kidney disease. | 2013 | Nefrologia | pmid:24089163 |
| del Pozo-Fernández C et al. | Compliance with objectives based on different guidelines (KDIGO/S.E.N.) and analysis of the individual variability of mineral metabolism in haemodialysis patients in the medium term. | 2013 | Nefrologia | pmid:24089159 |
| Lawrence JA et al. | Oral paricalcitol (19-nor-1,25-dihydroxyvitamin D2) in women receiving chemotherapy for metastatic breast cancer: a feasibility trial. | 2013 | Cancer Biol. Ther. | pmid:23760489 |
| Panizo S et al. | Vitamin D receptor activation, left ventricular hypertrophy and myocardial fibrosis. | 2013 | Nephrol. Dial. Transplant. | pmid:24013683 |
| Navarro-González JF et al. | Anti-inflammatory profile of paricalcitol in hemodialysis patients: a prospective, open-label, pilot study. | 2013 | J Clin Pharmacol | pmid:23426718 |
| Bellasi A et al. | Paricalcitol and cardiorenal outcome: from the IMPACT study to clinical practice. | 2013 | Blood Purif. | pmid:23736115 |
| Wu-Wong JR et al. | Mapping the time-dependent effects of paricalcitol on serum calcium, phosphorus and parathyroid hormone levels in 5/6 nephrectomized uremic rats. | 2013 | Life Sci. | pmid:23261531 |
| Han T et al. | Meta-analysis: the efficacy and safety of paricalcitol for the treatment of secondary hyperparathyroidism and proteinuria in chronic kidney disease. | 2013 | Biomed Res Int | pmid:23509710 |
| Pacini S et al. | Effects of vitamin D3 and paricalcitol on immature cardiomyocytes: a novel role for vitamin D analogs in the prevention of cardiovascular diseases. | 2013 | Nutrients | pmid:23749205 |
| Hwang HS et al. | Pretreatment with paricalcitol attenuates inflammation in ischemia-reperfusion injury via the up-regulation of cyclooxygenase-2 and prostaglandin E2. | 2013 | Nephrol. Dial. Transplant. | pmid:23229926 |
| Ramos R et al. | Effectiveness of treatment with oral paricalcitol in patients on peritoneal dialysis: a Spanish multicenter study. | 2013 | Clin. Nephrol. | pmid:23320973 |
| Coyne DW et al. | Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study. | 2013 | Nephrol. Dial. Transplant. | pmid:23787544 |
| Kim CS et al. | Paricalcitol attenuates 4-hydroxy-2-hexenal-induced inflammation and epithelial-mesenchymal transition in human renal proximal tubular epithelial cells. | 2013 | PLoS ONE | pmid:23690997 |
| Ong LM et al. | Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism. | 2013 | Nephrology (Carlton) | pmid:23311404 |
| Guerrero F et al. | The effect of vitamin D derivatives on vascular calcification associated with inflammation. | 2012 | Nephrol. Dial. Transplant. | pmid:22025118 |
| Pohjolainen V et al. | Left ventricular periostin gene expression is associated with fibrogenesis in experimental renal insufficiency. | 2012 | Nephrol. Dial. Transplant. | pmid:21712488 |
| Noertersheuser PA et al. | Exposure-clinical response analysis of paricalcitol in patients with chronic kidney disease (stage 5) on hemodialysis or peritoneal dialysis. | 2012 | J Clin Pharmacol | pmid:21940716 |
| Hansen D et al. | Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol. | 2012 | Nephrol. Dial. Transplant. | pmid:22140123 |
| Kovesdy CP et al. | Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial. | 2012 | Am. J. Kidney Dis. | pmid:21885174 |
| Komaba H and Fukagawa M | Vitamin D and secreted Klotho: a long-awaited panacea for vascular calcification? | 2012 | Kidney Int. | pmid:23203019 |
| Kant KS et al. | Converting to doxercalciferol capsules from intravenous paricalcitol or doxercalciferol. | 2012 | J Ren Nutr | pmid:21652220 |
| Verouti SN et al. | Vitamin D receptor activators upregulate and rescue podocalyxin expression in high glucose-treated human podocytes. | 2012 | Nephron Exp. Nephrol. | pmid:23548800 |
| Izquierdo MJ et al. | Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients. | 2012 | BMC Nephrol | pmid:23186077 |
Paricalcitol
Paricalcitol is a lipid of Sterol Lipids (ST) class. Paricalcitol is associated with abnormalities such as Vitamin D Deficiency. The involved functions are known as Hypertrophy, Left Ventricular. Paricalcitol often locates in Blood.
Cross Reference
Introduction
To understand associated biological information of Paricalcitol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Paricalcitol?
Paricalcitol is suspected in Vitamin D Deficiency and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
No disease MeSH terms mapped to the current reference collection.
PubChem Associated disorders and diseases
What pathways are associated with Paricalcitol
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Paricalcitol?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Paricalcitol?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Paricalcitol?
There are no associated biomedical information in the current reference collection.
What genes are associated with Paricalcitol?
There are no associated biomedical information in the current reference collection.
What common seen animal models are associated with Paricalcitol?
There are no associated biomedical information in the current reference collection.